Beacon Investment Advisory Services Inc. Sells 5,951 Shares of Stryker Corporation $SYK

Key Points

• Beacon Investment Advisory Services reduced its Stryker position by 10.7%, selling 5,951 shares and retaining 49,723 shares valued at approximately $15.7 million. Institutional investors and hedge funds collectively own 77.09% of SYK.
• Stryker reported quarterly earnings of $3.69 per share, exceeding estimates of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company projected fiscal 2026 earnings of $14.95–$15.10 per share.
• Stryker declared a quarterly dividend of $0.88, equivalent to $3.52 annually and a 1.0% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $386.28, while company insiders sold more than $100 million in shares over the past 90 days.

Beacon Investment Advisory Services Inc. decreased its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 10.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 49,723 shares of the medical technology company's stock after selling 5,951 shares during the quarter. Beacon Investment Advisory Services Inc.'s holdings in Stryker were worth $15,655,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of SYK. Varma Mutual Pension Insurance Co lifted its holdings in shares of Stryker by 10.5% in the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company's stock valued at $18,842,000 after purchasing an additional 5,100 shares in the last quarter. QRG Capital Management Inc. grew its holdings in Stryker by 7.4% during the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company's stock worth $21,281,000 after buying an additional 4,186 shares in the last quarter. Swedbank AB grew its holdings in Stryker by 6.6% during the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company's stock worth $45,349,000 after buying an additional 7,934 shares in the last quarter. Crossmark Global Holdings Inc. raised its position in Stryker by 31.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company's stock valued at $9,426,000 after buying an additional 6,367 shares during the last quarter. Finally, Cibc World Market Inc. lifted its stake in Stryker by 11.9% during the 4th quarter. Cibc World Market Inc. now owns 157,822 shares of the medical technology company's stock valued at $55,470,000 after acquiring an additional 16,790 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

NYSE SYK opened at $338.85 on Friday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a 50-day simple moving average of $320.11 and a 200 day simple moving average of $334.13. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The company has a market capitalization of $129.97 billion, a PE ratio of 35.11, a price-to-earnings-growth ratio of 2.15 and a beta of 0.76.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to analysts' expectations of $6.58 billion. During the same period in the previous year, the company earned $3.13 earnings per share. The company's quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker's dividend payout ratio is presently 36.48%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on SYK shares. UBS Group assumed coverage on shares of Stryker in a research note on Tuesday, July 28th. They issued a "buy" rating and a $400.00 target price for the company. Leerink Partners reduced their price objective on shares of Stryker from $410.00 to $407.00 and set an "outperform" rating for the company in a research report on Friday, June 5th. Wells Fargo & Company cut their target price on Stryker from $456.00 to $418.00 and set an "overweight" rating on the stock in a research note on Friday, May 1st. Evercore set a $350.00 target price on Stryker in a report on Monday, July 6th. Finally, Citizens Jmp decreased their price target on Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $386.28.

Insider Buying and Selling at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company's stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm's stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company's stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 323,264 shares of company stock valued at $100,659,489. Company insiders own 4.60% of the company's stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source